Previous studies showed that tempol, an antioxidant, and antibiotic treatments resulted in reduction of the genus Lactobacillus, thus improving obesity, NAFLD, and insulin resistance via inhibition of intestinal FXR signaling (9, 11). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.